¼º°¨¿°Áõ(STD) Áø´Ü ½ÃÀå º¸°í¼ : À¯Çüº°, µð¹ÙÀ̽º À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2025-2033³â)
Sexually Transmitted Disease Diagnostics Market Report by Type, Device Type (Laboratory Devices, Point of Care Devices), End User (Laboratory Testing, Point of Care Testing), and Region 2025-2033
»óǰÄÚµå
:
1635878
¸®¼Ä¡»ç
:
IMARC Group
¹ßÇàÀÏ
:
2025³â 01¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 143 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¼º°¨¿°Áõ(STD) Áø´Ü ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 1,090¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â±îÁö ½ÃÀå ±Ô¸ð°¡ 1,649¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2025-2033³â ¿¬Æò±Õ ¼ºÀå·ü(CAGR)Àº 4.47%¿¡ ´Þ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ¼ºº´ À¯º´·ü Áõ°¡, Á¶±â Áø´Ü¿¡ ´ëÇÑ ´ëÁßÀÇ ÀÎ½Ä Áõ°¡, °¡Á¤¿ë ¼ºº´ °Ë»ç ŰƮÀÇ µµÀÔ µîÀÌ ½ÃÀåÀ» ÁÖµµÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù.
¼º°¨¿°Áõ(STD) Áø´ÜÀº ¼ºº´ÀÇ Á¸À縦 È®ÀÎÇϰųª È®ÀÎÇϱâ À§ÇØ ½ÃÇàÇÏ´Â °Ë»ç, ½ÃÇè, ¸éºÀ ¹è¾ç µîÀ» ¸»ÇÕ´Ï´Ù. ¿©±â¿¡´Â ƯÁ¤ ¼ºº´ÀÇ Ç×ü³ª Ç׿øÀÇ Á¸À縦 °ËÃâÇϱâ À§ÇÑ Ç÷¾×, ü¾× »ùÇÃ, ¼Òº¯ °Ë»ç°¡ Æ÷ÇԵ˴ϴÙ. ¼º±â Æ÷Áø, Ŭ¶ó¹Ìµð¾Æ, ÀÓÁú, ¸Åµ¶, À½ºÎ À̰¡, Æ®¸®Äڸ𳪽º, ÈÄõ¼º ¸é¿ª °áÇÌ ÁõÈıº(AIDS), ¼¼±Õ¼º Áú¿°, ¿È, ¾Æ±¸Ã¢ µî ´Ù¾çÇÑ ¼ºº´ ¹× °¨¿°¼º ÁúȯÀÇ °ËÃâ ¹× °Ë»ç¿¡ ³Î¸® »ç¿ëµË´Ï´Ù. °¨¿°À¸·ÎºÎÅÍ Å¾Ƹ¦ º¸È£Çϰí Áúº´ÀÇ È®»êÀ» ÃÖ¼ÒÈÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Áø´Ü ¹æ¹ýÀº ¶ÇÇÑ Àå±âÀûÀÎ À§Çè °¡´É¼ºÀ» ÁÙÀ̰í, ÀڽۨÀ» ³ôÀ̸ç, Àǻ簡 Áúº´°ú ±× ¿øÀο¡ ´ëÇÑ ±ÍÁßÇÑ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.
¼º°¨¿°Áõ(STD) Áø´Ü ½ÃÀå µ¿Çâ:
¹«¹æºñ ¼º°ü°è ¹× ¾à¹° ³²¿ëÀ¸·Î ÀÎÇÑ ¼º°¨¿°Áõ(STD) À¯º´·üÀÇ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀ̸ç, STD Áø´ÜÁ¦´Â ¹ÚÅ׸®¾Æ, ¹ÙÀÌ·¯½º, ±â»ýÃæ µî ´Ù¾çÇÑ STD ¿øÀÎ ¹°ÁúÀ» ³ôÀº Á¤È®µµ¿Í ½Å·Ú¼ºÀ¸·Î °ËÃâÇÏ¿© ÀÇ·á ¼ºñ½º Á¦°øÀÚ°¡ ÀûÀýÇÑ Ä¡·á¹ýÀ» °áÁ¤ÇÏ°í ¸ðü¿¡¼ ¿µ¾Æ·ÎÀÇ Áúº´ ÀüÆÄ¸¦ ¿¹¹æÇϰí ȯÀÚÀÇ ÀÓ»ó °á°ú¸¦ °³¼±ÇÏ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ¿©±â¿¡ ´õÇØ ºÒÀÓ, ¼±Ãµ¼º Àå¾Ö, ¾Ï, ½Ç¸í, »À ±âÇü, ³ú ¼Õ»ó, Á¤½Å Áöü µî Àå±âÀûÀÎ ÇÕº´ÁõÀ» ¿¹¹æÇÒ ¼ö ÀÖ´Â ¼ºº´ÀÇ Á¶±â ¹ß°ß ¹× Áø´Ü¿¡ ´ëÇÑ ´ëÁßÀÇ ÀνÄÀÌ ³ô¾ÆÁø °ÍÀÌ ¶Ç ´Ù¸¥ ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±³À° Ä·ÆäÀÎ, ¼¼¹Ì³ª, ¼Ò¼È ¹Ìµð¾î ±¤°í¸¦ ÅëÇØ ¼º °Ç° ¹× ¼ºº´ °Ë»ç¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀÌ°í °ü·Ã »çȸÀû Æí°ßÀ» ¾ø¾Ö±â À§ÇÑ ´Ù¾çÇÑ Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê°¡ ½ÃÇàµÇ¸é¼ ½ÃÀå ¼ºÀå¿¡ ź·ÂÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºñ¿ë È¿À²ÀûÀ̰í, ¾ÈÀüÇϰí, Á¤È®Çϰí, Æí¸®Çϸç, ºü¸¥ °á°ú¿Í ÇÁ¶óÀ̹ö½Ã¸¦ º¸ÀåÇÏ´Â °¡Á¤¿ë ¼ºº´ °Ë»ç ŰƮÀÇ µµÀÔÀº ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÃÖ±Ù °³ÀÎÀÇ À½ºÎ µðÁöÅÐ À̹ÌÁö¸¦ ºÐ¼®ÇÏ¿© ¼ºº´À» Áø´ÜÇÒ ¼ö ÀÖ´Â ÀΰøÁö´É(AI) ±â¹Ý ¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼ÇÀÇ °³¹ßÀº ¼ºº´ °Ë»ç¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» °³¼±ÇÏ°í ±â¹Ð¼ºÀ» À¯ÁöÇÏ¸ç °³ÀÎ µ¥ÀÌÅ͸¦ º¸È£ÇÔÀ¸·Î½á ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÇコÄÉ¾î »ê¾÷ÀÇ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀå, E-Commerce Ç÷§Æû¿¡¼ ¼ºº´ Áø´Ü ŰƮ¸¦ ½±°Ô ±¸ÇÒ ¼ö ÀÖ°í, »õ·Î¿î Áø´Ü ±â¼ú ¿¬±¸°³¹ß(R&D)¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡ µî ´Ù¸¥ ¿äÀε鵵 ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
º» º¸°í¼¿¡¼ ´Ù·ç´Â ÁÖ¿ä Áú¹®
- ¼¼°è ¼º°¨¿°Áõ(STD) Áø´Ü ½ÃÀåÀº Áö±Ý±îÁö ¾î¶»°Ô ¼ºÀåÇØ ¿ÔÀ»±î?
- ¼¼°è ¼º°¨¿°Áõ(STD) Áø´Ü ½ÃÀåÀÇ ½ÃÀå ÃËÁø¿äÀÎ, ½ÃÀå ¾ïÁ¦¿äÀÎ, ½ÃÀå ±âȸ´Â ¹«¾ùÀΰ¡?
- ¼¼°è ¼ºº´ Áø´Ü ½ÃÀå¿¡ ¹ÌÄ¡´Â °¢ ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ°¡ ¼ºº´ Áø´Ü ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº ¹«¾ùÀΰ¡?
- ÁÖ¿ä Áö¿ª ½ÃÀåÀº?
- ¼º°¨¿°Áõ(STD) Áø´Ü ½ÃÀå¿¡¼ °¡Àå ¸Å·ÂÀûÀÎ ±¹°¡´Â ¾îµðÀϱî?
- À¯Çüº° ½ÃÀå ºÐ¼®Àº?
- ¼º°¨¿°Áõ(STD) Áø´Ü ½ÃÀå¿¡¼ °¡Àå ¸Å·ÂÀûÀÎ À¯ÇüÀº?
- µð¹ÙÀ̽º À¯Çüº° ½ÃÀå ºÐ¼®Àº?
- ¼º°¨¿°Áõ(STD) Áø´Ü ½ÃÀå¿¡¼ °¡Àå ¸Å·ÂÀûÀÎ µð¹ÙÀ̽º À¯ÇüÀº?
- ÃÖÁ¾»ç¿ëÀÚº° ½ÃÀå ºÐ¼®Àº ¾î¶»°Ô µÇ´Â°¡?
- ¼º°¨¿°Áõ(STD) Áø´Ü ½ÃÀå¿¡¼ °¡Àå ¸Å·ÂÀûÀÎ ÃÖÁ¾»ç¿ëÀÚ´Â?
- ¼º°¨¿°Áõ(STD) Áø´Ü ¼¼°è ½ÃÀåÀÇ °æÀï ±¸µµ´Â?
- ¼º°¨¿°Áõ(STD) Áø´Ü ¼¼°è ½ÃÀåÀÇ ÁÖ¿ä Ç÷¹À̾î/±â¾÷Àº?
¸ñÂ÷
Á¦1Àå ¼¹®
Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý
- Á¶»ç ¸ñÀû
- ÀÌÇØ°ü°èÀÚ
- µ¥ÀÌÅÍ ¼Ò½º
- ½ÃÀå ÃßÁ¤
- Á¶»ç ¹æ¹ý
Á¦3Àå ÁÖ¿ä ¿ä¾à
Á¦4Àå ¼Ò°³
Á¦5Àå ¼¼°è ¼º°¨¿°Áõ(STD) Áø´Ü ½ÃÀå
- ½ÃÀå °³¿ä
- ½ÃÀå ½ÇÀû
- COVID-19ÀÇ ¿µÇâ
- ½ÃÀå ¿¹Ãø
Á¦6Àå ½ÃÀå ³»¿ª : À¯Çüº°
- Ŭ¶ó¹Ìµð¾Æ °Ë»ç
- ¸Åµ¶ °Ë»ç
- ÀÓÁú °Ë»ç
- ´Ü¼øÆ÷Áø¹ÙÀÌ·¯½º °Ë»ç
- ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º °Ë»ç
- Àΰ£¸é¿ª°áÇ̹ÙÀÌ·¯½º °Ë»ç
- ¿¬¼ºÇϰ¨ °Ë»ç
- ±âŸ
Á¦7Àå ½ÃÀå ³»¿ª : µð¹ÙÀ̽º À¯Çüº°
- ½ÇÇèÀåÄ¡
- ½ÃÀå µ¿Çâ
- ÁÖ¿ä ºÎ¹®
- ¼¸Ö »çÀÌŬ·¯-PCR
- Ãø¹æÀ¯µ¿ ¸®´õ
- À¯¼¼Æ÷ ºÐ¼®±â
- Èí±¤ ¸¶ÀÌÅ©·ÎÇ÷¹ÀÌÆ® ¸®´õ-È¿¼Ò°áÇո鿪ÈíÂø ÃøÁ¤¹ý(ELISA)
- ±âŸ
- ½ÃÀå ¿¹Ãø
- POC(Point of Care)(PoC) µð¹ÙÀ̽º
- ½ÃÀå µ¿Çâ
- ÁÖ¿ä ºÎ¹®
- ÀüÈ Ä¨(¹Ì¼¼À¯Ã¼+ICT)
- ÈÞ´ë¿ë/º¥Ä¡Åé/½Å¼Ó Áø´Ü ŰƮ
- ½ÃÀå ¿¹Ãø
Á¦8Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°
- ÀÓ»ó °Ë»ç
- POC(Point of Care)(PoC) °Ë»ç
Á¦9Àå ½ÃÀå ³»¿ª : Áö¿ªº°
- ºÏ¹Ì
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- ÀϺ»
- Àεµ
- Çѱ¹
- È£ÁÖ
- Àεµ³×½Ã¾Æ
- ±âŸ
- À¯·´
- µ¶ÀÏ
- ÇÁ¶û½º
- ¿µ±¹
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ·¯½Ã¾Æ
- ±âŸ
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦10Àå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ
- °³¿ä
- ¼ºÀå ÃËÁø¿äÀÎ
- ¼ºÀå ¾ïÁ¦¿äÀÎ
- ±âȸ
Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®
Á¦12Àå Porter's Five Forces ºÐ¼®
- °³¿ä
- ±¸¸ÅÀÚÀÇ ±³¼··Â
- °ø±Þ ±â¾÷ÀÇ ±³¼··Â
- °æÀï Á¤µµ
- ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
Á¦13Àå °¡°Ý ºÐ¼®
Á¦14Àå °æÀï ±¸µµ
- ½ÃÀå ±¸Á¶
- ÁÖ¿ä ±â¾÷
- ÁÖ¿ä ±â¾÷ °³¿ä
- Abbott Laboratories
- Becton Dickinson and Company
- BioMerieux SA
- Bio-Rad Laboratories Inc.
- Cepheid(Danaher Corporation)
- F. Hoffmann-La Roche AG
- Hologic Inc.
- Qiagen N.V.
- Quidel Corporation
- Siemens Healthineers AG(Siemens AG)
ksm
¿µ¹® ¸ñÂ÷
The global sexually transmitted disease (STD) diagnostics market size reached USD 109.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 164.9 Billion by 2033, exhibiting a growth rate (CAGR) of 4.47% during 2025-2033. The rising prevalence of STDs, increasing awareness among the masses regarding early diagnosis, and the introduction of at-home STD testing kits represent some of the key factors driving the market.
Sexually transmitted disease (STD) diagnostics refer to examinations, tests, and swab cultures performed to identify and confirm the presence of STDs. It includes blood, fluid sample, and urine tests to detect the presence of antibodies or antigens of certain STDs. It is widely used to detect and screen various sexually transmitted diseases and infections, such as genital herpes, chlamydia, gonorrhea, syphilis, pubic lice, trichomoniasis, acquired immune deficiency syndrome (AIDS), bacterial vaginosis, scabies, and chancroid. STD diagnostics aids in early detection and accurate treatment, prevents infertility, protects unborn children from infection, and minimizes the spread of diseases. These diagnostic methods also help in reducing the chance of long-term risks, boosting confidence, and providing physicians with valuable insight into diseases and their causes.
Sexually Transmitted Disease (STD) Diagnostics Market Trends:
The rising prevalence of sexually transmitted diseases (STDs) due to unprotected sexual intercourse and drug abuse is one of the key factors driving the market growth. STD diagnostics are widely used to detect various STD-causing agents, such as bacteria, viruses, and parasites, with high accuracy and reliability that aids healthcare providers in determining suitable treatment, preventing disease transmission from mothers to infants, and improving clinical outcomes for patients. In addition to this, the increasing awareness among the masses regarding early detection and diagnosis of STDs, which can prevent long-term complications, such as infertility, congenital disabilities, cancer, blindness, bone deformities, brain damage, and mental retardation, is acting as another growth-inducing factor. Furthermore, the implementation of various government initiatives to raise awareness regarding sexual health and STD testing and remove the social stigma associated with it through educational campaigns, seminars, and social media advertisements are providing an impetus to the market growth. Additionally, the introduction of at-home STD testing kits that are cost-effective, safe, accurate, and convenient, provide faster results, and maintain privacy is positively influencing the market growth. Moreover, the recent development of artificial intelligence (AI) - based mobile applications that can diagnose STDs by analyzing digital images of an individual's private parts, thus improving access to STD screenings, maintaining confidentiality, and protecting personal data, is favoring the market growth. Other factors, including significant growth in the healthcare industry, easy availability of STD diagnostics kits across e-commerce platforms, and increasing investment in the research and development (R&D) of novel diagnostic technologies, are anticipated to drive the market growth.
Key Market Segmentation:
Type Insights:
- Chlamydia Testing
- Syphilis Testing
- Gonorrhea Testing
- Herpes Simplex Virus Testing
- Human Papilloma Virus Testing
- Human Immunodeficiency Virus Testing
- Chancroid Testing
- Others
Device Type Insights:
- Laboratory Devices
- Thermal Cycler - PCR
- Lateral Flow Readers
- Flow Cytometers
- Absorbance Microplate Reader - Enzyme Linked Immunosorbent Assay (ELISA)
- Others
- Point of Care (PoC) Devices
- Phone Chips (Microfluidics + ICT)
- Portable/Bench Top/Rapid Diagnostic Kits
End User Insights:
- Laboratory Testing
- Point of Care (PoC) Testing
Regional Insights:
- North America
- United States
- Canada
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
- The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for sexually transmitted disease (STD) diagnostics. Some of the factors driving the North America sexually transmitted disease (STD) diagnostics market included the rising prevalence of STDs, extensive research and development (R&D) activities, and significant growth in the healthcare industry.
Competitive Landscape:
- The report has also provided a comprehensive analysis of the competitive landscape in the global sexually transmitted disease (STD) diagnostics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Abbott Laboratories, Becton Dickinson and Company, BioMerieux SA, Bio-Rad Laboratories Inc., Cepheid (Danaher Corporation), F. Hoffmann-La Roche AG, Hologic Inc., Qiagen N.V., Quidel Corporation, Siemens Healthineers AG (Siemens AG), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report:
- How has the global sexually transmitted disease (STD) diagnostics market performed so far, and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global sexually transmitted disease (STD) diagnostics market?
- What is the impact of each driver, restraint, and opportunity on the global sexually transmitted disease (STD) diagnostics market?
- What are the key regional markets?
- Which countries represent the most attractive sexually transmitted disease (STD) diagnostics market?
- What is the breakup of the market based on the type?
- Which is the most attractive type in the sexually transmitted disease (STD) diagnostics market?
- What is the breakup of the market based on the device type?
- Which is the most attractive device type in the sexually transmitted disease (STD) diagnostics market?
- What is the breakup of the market based on end user?
- Which is the most attractive end user in the sexually transmitted disease (STD) diagnostics market?
- What is the competitive structure of the global sexually transmitted disease (STD) diagnostics market?
- Who are the key players/companies in the global sexually transmitted disease (STD) diagnostics market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Sexually Transmitted Disease (STD) Diagnostics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Chlamydia Testing
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Syphilis Testing
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Gonorrhea Testing
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Herpes Simplex Virus Testing
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Human Papilloma Virus Testing
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Human Immunodeficiency Virus Testing
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
- 6.7 Chancroid Testing
- 6.7.1 Market Trends
- 6.7.2 Market Forecast
- 6.8 Others
- 6.8.1 Market Trends
- 6.8.2 Market Forecast
7 Market Breakup by Device Type
- 7.1 Laboratory Devices
- 7.1.1 Market Trends
- 7.1.2 Key Segments
- 7.1.2.1 Thermal Cyclers - PCR
- 7.1.2.2 Lateral Flow Readers
- 7.1.2.3 Flow Cytometers
- 7.1.2.4 Absorbance Microplate Reader - Enzyme Linked Immunosorbent Assay (ELISA)
- 7.1.2.5 Others
- 7.1.3 Market Forecast
- 7.2 Point of Care (PoC) Devices
- 7.2.1 Market Trends
- 7.2.2 Key Segments
- 7.2.2.1 Phone Chips (Microfluidics + ICT)
- 7.2.2.2 Portable/Bench Top/Rapid Diagnostic Kits
- 7.2.3 Market Forecast
8 Market Breakup by End User
- 8.1 Laboratory Testing
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Point of Care Testing
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
- 10.1 Overview
- 10.2 Drivers
- 10.3 Restraints
- 10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Abbott Laboratories
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Becton Dickinson and Company
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 BioMerieux SA
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Bio-Rad Laboratories Inc.
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Cepheid (Danaher Corporation)
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 SWOT Analysis
- 14.3.6 F. Hoffmann-La Roche AG
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.7 Hologic Inc.
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 Qiagen N.V.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Quidel Corporation
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 Siemens Healthineers AG (Siemens AG)
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
°ü·ÃÀÚ·á